Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts
Supraphysiological testosterone (SPT) produces clinical and quality-of-life benefits in subsets of castration-resistant prostate cancer patients. Molecular characteristics associated with a response have not been identified yet. This study indicated sustained repressions of ARv7 and E2F transcriptional outputs, and the DNA damage response program as hallmarks of a durable SPT response.
